Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats.
Identifieur interne : 001D84 ( Main/Corpus ); précédent : 001D83; suivant : 001D85Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats.
Auteurs : Walter Adriani ; Sabine Spijker ; Véronique Deroche-Gamonet ; Giovanni Laviola ; Michel Le Moal ; August B. Smit ; Pier Vincenzo PiazzaSource :
- The Journal of neuroscience : the official journal of the Society for Neuroscience [ 1529-2401 ] ; 2003.
English descriptors
- KwdEn :
- Animals (MeSH), Behavior, Animal (drug effects), Behavior, Animal (physiology), Critical Period, Psychological (MeSH), Gene Expression (drug effects), Injections, Intravenous (MeSH), Male (MeSH), Mesencephalon (drug effects), Mesencephalon (metabolism), Motor Activity (drug effects), Nervous System (drug effects), Nicotine (pharmacology), Protein Subunits (genetics), Protein Subunits (metabolism), RNA, Messenger (metabolism), Rats (MeSH), Rats, Sprague-Dawley (MeSH), Receptors, Nicotinic (genetics), Receptors, Nicotinic (metabolism), Reinforcement, Psychology (MeSH), Self Administration (MeSH), Sexual Maturation (physiology), Substantia Nigra (drug effects), Substantia Nigra (metabolism), Time (MeSH), Tobacco Use Disorder (etiology), Ventral Tegmental Area (drug effects), Ventral Tegmental Area (metabolism).
- MESH :
- chemical , genetics : Protein Subunits, Receptors, Nicotinic.
- chemical , metabolism : Protein Subunits, RNA, Messenger, Receptors, Nicotinic.
- chemical , pharmacology : Nicotine.
- drug effects : Behavior, Animal, Gene Expression, Mesencephalon, Motor Activity, Nervous System, Substantia Nigra, Ventral Tegmental Area.
- etiology : Tobacco Use Disorder.
- metabolism : Mesencephalon, Substantia Nigra, Ventral Tegmental Area.
- physiology : Behavior, Animal, Sexual Maturation.
- Animals, Critical Period, Psychological, Injections, Intravenous, Male, Rats, Rats, Sprague-Dawley, Reinforcement, Psychology, Self Administration, Time.
Abstract
Epidemiological studies indicate that there is an increased likelihood for the development of nicotine addiction when cigarette smoking starts early during adolescence. These observations suggest that adolescence could be a "critical" ontogenetic period, during which drugs of abuse have distinct effects responsible for the development of dependence later in life. We compared the long-term behavioral and molecular effects of repeated nicotine treatment during either periadolescence or postadolescence in rats. It was found that exposure to nicotine during periadolescence, but not a similar exposure in the postadolescent period, increased the intravenous self-administration of nicotine and the expression of distinct subunits of the ligand-gated acetylcholine receptor in adult animals. Both these changes indicated an increased sensitivity to the addictive properties of nicotine. In conclusion, adolescence seems to be a critical developmental period, characterized by enhanced neurobehavioral vulnerability to nicotine.
PubMed: 12805310
PubMed Central: PMC6740776
Links to Exploration step
pubmed:12805310Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats.</title><author><name sortKey="Adriani, Walter" sort="Adriani, Walter" uniqKey="Adriani W" first="Walter" last="Adriani">Walter Adriani</name><affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale U588, Université V. Segalen, Bordeaux 2, Domaine de Carreire, 33077 Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Spijker, Sabine" sort="Spijker, Sabine" uniqKey="Spijker S" first="Sabine" last="Spijker">Sabine Spijker</name></author><author><name sortKey="Deroche Gamonet, Veronique" sort="Deroche Gamonet, Veronique" uniqKey="Deroche Gamonet V" first="Véronique" last="Deroche-Gamonet">Véronique Deroche-Gamonet</name></author><author><name sortKey="Laviola, Giovanni" sort="Laviola, Giovanni" uniqKey="Laviola G" first="Giovanni" last="Laviola">Giovanni Laviola</name></author><author><name sortKey="Le Moal, Michel" sort="Le Moal, Michel" uniqKey="Le Moal M" first="Michel" last="Le Moal">Michel Le Moal</name></author><author><name sortKey="Smit, August B" sort="Smit, August B" uniqKey="Smit A" first="August B" last="Smit">August B. Smit</name></author><author><name sortKey="Piazza, Pier Vincenzo" sort="Piazza, Pier Vincenzo" uniqKey="Piazza P" first="Pier Vincenzo" last="Piazza">Pier Vincenzo Piazza</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12805310</idno><idno type="pmid">12805310</idno><idno type="pmc">PMC6740776</idno><idno type="wicri:Area/Main/Corpus">001D84</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001D84</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats.</title><author><name sortKey="Adriani, Walter" sort="Adriani, Walter" uniqKey="Adriani W" first="Walter" last="Adriani">Walter Adriani</name><affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale U588, Université V. Segalen, Bordeaux 2, Domaine de Carreire, 33077 Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Spijker, Sabine" sort="Spijker, Sabine" uniqKey="Spijker S" first="Sabine" last="Spijker">Sabine Spijker</name></author><author><name sortKey="Deroche Gamonet, Veronique" sort="Deroche Gamonet, Veronique" uniqKey="Deroche Gamonet V" first="Véronique" last="Deroche-Gamonet">Véronique Deroche-Gamonet</name></author><author><name sortKey="Laviola, Giovanni" sort="Laviola, Giovanni" uniqKey="Laviola G" first="Giovanni" last="Laviola">Giovanni Laviola</name></author><author><name sortKey="Le Moal, Michel" sort="Le Moal, Michel" uniqKey="Le Moal M" first="Michel" last="Le Moal">Michel Le Moal</name></author><author><name sortKey="Smit, August B" sort="Smit, August B" uniqKey="Smit A" first="August B" last="Smit">August B. Smit</name></author><author><name sortKey="Piazza, Pier Vincenzo" sort="Piazza, Pier Vincenzo" uniqKey="Piazza P" first="Pier Vincenzo" last="Piazza">Pier Vincenzo Piazza</name></author></analytic><series><title level="j">The Journal of neuroscience : the official journal of the Society for Neuroscience</title><idno type="eISSN">1529-2401</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Behavior, Animal (drug effects)</term><term>Behavior, Animal (physiology)</term><term>Critical Period, Psychological (MeSH)</term><term>Gene Expression (drug effects)</term><term>Injections, Intravenous (MeSH)</term><term>Male (MeSH)</term><term>Mesencephalon (drug effects)</term><term>Mesencephalon (metabolism)</term><term>Motor Activity (drug effects)</term><term>Nervous System (drug effects)</term><term>Nicotine (pharmacology)</term><term>Protein Subunits (genetics)</term><term>Protein Subunits (metabolism)</term><term>RNA, Messenger (metabolism)</term><term>Rats (MeSH)</term><term>Rats, Sprague-Dawley (MeSH)</term><term>Receptors, Nicotinic (genetics)</term><term>Receptors, Nicotinic (metabolism)</term><term>Reinforcement, Psychology (MeSH)</term><term>Self Administration (MeSH)</term><term>Sexual Maturation (physiology)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (metabolism)</term><term>Time (MeSH)</term><term>Tobacco Use Disorder (etiology)</term><term>Ventral Tegmental Area (drug effects)</term><term>Ventral Tegmental Area (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Protein Subunits</term><term>Receptors, Nicotinic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Protein Subunits</term><term>RNA, Messenger</term><term>Receptors, Nicotinic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Nicotine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Gene Expression</term><term>Mesencephalon</term><term>Motor Activity</term><term>Nervous System</term><term>Substantia Nigra</term><term>Ventral Tegmental Area</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tobacco Use Disorder</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Mesencephalon</term><term>Substantia Nigra</term><term>Ventral Tegmental Area</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Behavior, Animal</term><term>Sexual Maturation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Critical Period, Psychological</term><term>Injections, Intravenous</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Reinforcement, Psychology</term><term>Self Administration</term><term>Time</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Epidemiological studies indicate that there is an increased likelihood for the development of nicotine addiction when cigarette smoking starts early during adolescence. These observations suggest that adolescence could be a "critical" ontogenetic period, during which drugs of abuse have distinct effects responsible for the development of dependence later in life. We compared the long-term behavioral and molecular effects of repeated nicotine treatment during either periadolescence or postadolescence in rats. It was found that exposure to nicotine during periadolescence, but not a similar exposure in the postadolescent period, increased the intravenous self-administration of nicotine and the expression of distinct subunits of the ligand-gated acetylcholine receptor in adult animals. Both these changes indicated an increased sensitivity to the addictive properties of nicotine. In conclusion, adolescence seems to be a critical developmental period, characterized by enhanced neurobehavioral vulnerability to nicotine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12805310</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>11</Issue><PubDate><Year>2003</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats.</ArticleTitle><Pagination><MedlinePgn>4712-6</MedlinePgn></Pagination><Abstract><AbstractText>Epidemiological studies indicate that there is an increased likelihood for the development of nicotine addiction when cigarette smoking starts early during adolescence. These observations suggest that adolescence could be a "critical" ontogenetic period, during which drugs of abuse have distinct effects responsible for the development of dependence later in life. We compared the long-term behavioral and molecular effects of repeated nicotine treatment during either periadolescence or postadolescence in rats. It was found that exposure to nicotine during periadolescence, but not a similar exposure in the postadolescent period, increased the intravenous self-administration of nicotine and the expression of distinct subunits of the ligand-gated acetylcholine receptor in adult animals. Both these changes indicated an increased sensitivity to the addictive properties of nicotine. In conclusion, adolescence seems to be a critical developmental period, characterized by enhanced neurobehavioral vulnerability to nicotine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adriani</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institut National de la Santé et de la Recherche Médicale U588, Université V. Segalen, Bordeaux 2, Domaine de Carreire, 33077 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spijker</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Deroche-Gamonet</LastName><ForeName>Véronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Laviola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Le Moal</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Smit</LastName><ForeName>August B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Piazza</LastName><ForeName>Pier Vincenzo</ForeName><Initials>PV</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003423" MajorTopicYN="N">Critical Period, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009420" MajorTopicYN="N">Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012054" MajorTopicYN="N">Reinforcement, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012646" MajorTopicYN="N">Self Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012741" MajorTopicYN="N">Sexual Maturation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014029" MajorTopicYN="N">Tobacco Use Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017557" MajorTopicYN="N">Ventral Tegmental Area</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12805310</ArticleId><ArticleId IdType="pii">23/11/4712</ArticleId><ArticleId IdType="pmc">PMC6740776</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Physiol. 1999 May 1;516 ( Pt 3):657-78</Citation><ArticleIdList><ArticleId IdType="pubmed">10200416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1999 Apr 30;868:611-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10414341</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 1999 Aug;11(8):2731-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10457169</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1999 Aug 20;10(12):2497-501</Citation><ArticleIdList><ArticleId IdType="pubmed">10574359</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 1999 Nov;23(7):993-1010</Citation><ArticleIdList><ArticleId IdType="pubmed">10580313</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1999 Dec 18;851(1-2):9-19</Citation><ArticleIdList><ArticleId IdType="pubmed">10642823</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2000 Jun;24(4):417-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10817843</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 Jun 1;20(11):4226-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10818158</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Dev. 2000 Sep;22 Suppl 1:S1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10984655</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2000 Oct;39(13):2570-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11044728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicotine Tob Res. 2000 Aug;2(3):263-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11082827</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2001 Feb 23;892(2):269-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11172774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Mar 1;21(5):1452-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11222635</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2001 Sep;12(5):343-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11710749</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2002 Aug;27(2):212-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12093595</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2003 Jan-Mar;27(1-2):19-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12732220</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2003 Jan-Mar;27(1-2):163-78</Citation><ArticleIdList><ArticleId IdType="pubmed">12732232</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Dev Brain Res. 1992 Aug 21;68(2):163-74</Citation><ArticleIdList><ArticleId IdType="pubmed">1394965</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 1991 Dec;12(12):467-73</Citation><ArticleIdList><ArticleId IdType="pubmed">1792691</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1991 Sep 26;325(13):968-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1881424</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1990 Apr 23;514(1):22-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2357527</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 1987 Apr;162(1):156-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2440339</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1989 May;52(5):1582-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2709014</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 1986 May;17(1):93-102</Citation><ArticleIdList><ArticleId IdType="pubmed">3720536</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1972 May 26;40(2):395-418</Citation><ArticleIdList><ArticleId IdType="pubmed">4537284</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychobiol. 1983 Mar;16(2):83-109</Citation><ArticleIdList><ArticleId IdType="pubmed">6339302</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1983 Feb;224(2):319-26</Citation><ArticleIdList><ArticleId IdType="pubmed">6822957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1995 Oct;275(1):345-57</Citation><ArticleIdList><ArticleId IdType="pubmed">7562570</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1995 Mar 2;374(6517):65-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7870173</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8401595</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Dev Brain Res. 1995 Nov 21;89(2):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">8612321</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 1996 Feb;86(2):214-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8633738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1996 Jul 18;382(6588):255-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8717040</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1997 Feb;129(3):277-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9084067</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1997 Jan;129(1):35-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9122361</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1997 Apr 14;8(6):1495-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9172161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 1997 Jul;57(3):543-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9218279</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1998 Jul;286(1):311-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9655874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001D84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:12805310
|texte= Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:12805310" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |